multiple myeloma

Anitocabtagene autoleucel, a cell therapy, is associated with sustained clinical responses in patients with heavily pretreated multiple myeloma, according to a report in medical news. The finding is notable for a disease where patients who have exhausted standard lines of treatment typically face poor outcomes. Clinicians are watching whether such CAR-T approaches can extend durable remissions.